Drug Type Biosimilar, Monoclonal antibody |
Synonyms Rituximab biosimilar, BI-695500 |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Follicular Lymphoma | Phase 3 | US | 01 Apr 2015 | |
Recurrent Follicular Lymphoma | Phase 3 | AT | 01 Apr 2015 | |
Recurrent Follicular Lymphoma | Phase 3 | BE | 01 Apr 2015 | |
Recurrent Follicular Lymphoma | Phase 3 | BG | 01 Apr 2015 | |
Recurrent Follicular Lymphoma | Phase 3 | HR | 01 Apr 2015 | |
Recurrent Follicular Lymphoma | Phase 3 | CZ | 01 Apr 2015 | |
Rheumatoid Arthritis | Phase 3 | US | 05 Sep 2012 | |
Rheumatoid Arthritis | Phase 3 | AR | 05 Sep 2012 | |
Rheumatoid Arthritis | Phase 3 | BE | 05 Sep 2012 | |
Rheumatoid Arthritis | Phase 3 | BG | 05 Sep 2012 |
Phase 1 | 95 | (BI 695500) | kchwhdybti(flpxfivxxv) = rzwryzeeop edvztjqofr (vwdatvbsfk, kavtsqovcx - wvheznxbgl) View more | - | 05 Sep 2018 | ||
MabThera+Rituximab (Rituximab (MabThera®)) | kchwhdybti(flpxfivxxv) = bdunmhgpnt edvztjqofr (vwdatvbsfk, qstplpnysd - ydvacahlkb) View more | ||||||
Phase 3 | 294 | (BI 695500) | tzlbiusjed(qporeqttrj) = sbgtkhqqzl rswmtbxyvl (cjloapsbjs, zowksppasi - hlqwzerfnp) View more | - | 30 Jan 2018 | ||
(Rituxan®) | tzlbiusjed(qporeqttrj) = fbxlzdhfik rswmtbxyvl (cjloapsbjs, ntpctfshxt - xxykygglru) View more | ||||||
Phase 3 | 91 | cgwhydjqhd(wfgljiwlhq) = vqlnzmzqro agctveavav (omdummrduz, tagxxqkbnp - sccifbgfxp) View more | - | 18 Jan 2018 | |||
Phase 3 | 2 | esrukvgrcn(ryjdzvioee) = vmvtyvdfei ncmvrmzjhs (qbefkzojzx, qujwzzrqwj - cnehbolbgd) View more | - | 30 Jan 2017 |